ClinChoice, a global Contract Research Organisation (CRO), has announced expanding its global footprint with the acquisition of Singapore-based startup CSI Medical Research (CSI).

CSI is a regional clinical CRO with professional staff and partners located across Southeast Asia (SEA), Australia and New Zealand (ANZ), to provide innovative and cost-effective clinical solutions.

Through this strategic acquisition, ClinChoice further broadens its global footprint and full-service capabilities in more than 30 countries throughout Asia, Europe and North America around the world.

In recent years, the overall environment and infrastructure to support clinical research in Southeast Asia have been significantly improved. With large population, improving economy, maturing regulatory processes and healthcare systems, the SEA has attracted increasing number of biotech and pharmaceutical companies to conduct clinical research and drug development trials in the region.

CSI, incorporated in 2017, has quickly grown into a prominent regional CRO with proven track record of executing clinical trials in Southeast Asia. The management team at CSI consists of seasoned clinical research professionals that had worked in some of the biggest names in the industry before establishing CSI.